Seattle

Greater Good Charities and Animal Planet’s Jackson Galaxy Kick-Off 3rd Annual Cat Pawsitive National High-Five Day Contest

Retrieved on: 
Monday, March 22, 2021
Jackson Galaxy, Cat, Galaxy, Homelessness, Animals, Organisms

Seattle, March 22, 2021 (GLOBE NEWSWIRE) -- To celebrate the success of The Jackson Galaxy Projects (JGP) life-saving Cat Pawsitive initiative, Greater Good Charities and Animal Planets Jackson Galaxy announce the 3rd AnnualCat Pawsitive National High-Five Day Contest.

Key Points: 
  • Seattle, March 22, 2021 (GLOBE NEWSWIRE) -- To celebrate the success of The Jackson Galaxy Projects (JGP) life-saving Cat Pawsitive initiative, Greater Good Charities and Animal Planets Jackson Galaxy announce the 3rd AnnualCat Pawsitive National High-Five Day Contest.
  • The annual National High-Five Day contest is a time to celebrate the success of Cat Pawsitive and the impact it has had on thousands of homeless cats as well as inspire cat parents across the U.S. to get involved, said Galaxy.
  • To date, Greater Good Charities has provided over $22 million in support for COVID-19 disaster-relief, including cash grants, in-kind supplies, and programmatic support.
  • To learn more about how Greater Good Charities is amplifying the good across the globe, please visit greatergood.org or follow us on Facebook , Instagram , Twitter or YouTube .

Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

Retrieved on: 
Monday, March 22, 2021
Corporate finance, Equity securities, Finance, Financial economics, Money, Stock market, Options, Warrant, Stock, Limited liability company

The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $2.88.

Key Points: 
  • The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $2.88.
  • Maxim Group LLC is acting as the sole placement agent in connection with the offering.
  • The gross proceeds to the Company from the registered direct offering are estimated to be approximately $50.0 million before deducting the placement agents fees and other estimated offering expenses.
  • The offering is expected to close on or about March 24, 2021, subject to the satisfaction of customary closing conditions.

LMN Architects Celebrates the Design and Construction Progress of the Lakeview Office Building

Retrieved on: 
Monday, March 22, 2021
LMN Architects, Lakeview, Lake View, Chicago, LMN, Kirkland, Washington, Chicago, Cities in the United States

Seattle, March 22, 2021 (GLOBE NEWSWIRE) -- LMN Architects is pleased to celebrate the construction progress of the Lakeview Office Building in Kirkland, Washington.

Key Points: 
  • Seattle, March 22, 2021 (GLOBE NEWSWIRE) -- LMN Architects is pleased to celebrate the construction progress of the Lakeview Office Building in Kirkland, Washington.
  • The Lakeview Office Building celebrates Kirkland's natural landscape and reflects an innovative use of materials and sustainable elements.
  • The new Lakeview Office Building complements the neighborhoods character while enhancing the prominent intersection of Lakeview Drive and Lake Washington Boulevard.
  • Jeremy Schoenfeld, Associate, LMN Architects, comments: Mass timber construction has the potential to revolutionize the construction industry by combining the tradition of wood construction, craftsmanship, sustainable materials, and technological innovation.

Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021

Retrieved on: 
Thursday, March 18, 2021
Health sciences, Life sciences, Branches of biology, Pharmaceutical industry, Immunology, Pharmacy, Medicinal chemistry, Pharmacodynamics, Medication, Autoimmunity, Biopharmaceutical, Agonist

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology.

Key Points: 
  • Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology.
  • Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.
  • Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.
  • This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S.

Greater Good Charities and Halo Announce Winners of the Fido Foster “Lucky Dog” National Photo Contest

Retrieved on: 
Wednesday, March 17, 2021
Animals, Domesticated animals, Fido, Lucky Dog, United States presidential pets, Subspecies of Canis lupus, Dog

Seattle, March 17, 2021 (GLOBE NEWSWIRE) -- Greater Good Charities and Halo pet food announce the winners of the Fido Foster Lucky Dog National Photo Contest, including the grand prize winner Zeus.

Key Points: 
  • Seattle, March 17, 2021 (GLOBE NEWSWIRE) -- Greater Good Charities and Halo pet food announce the winners of the Fido Foster Lucky Dog National Photo Contest, including the grand prize winner Zeus.
  • The Fido Foster Lucky Dog Photo Contest is a time to not only celebrate amazing dogs that overcame adversity but to give back to the foster volunteers, adopters and animal welfare organizations that saved them, said Liz Baker, CEO of Greater Good Charities.
  • From February 25 until March 9, dog fosters and adopters were invited to visit FidoFoster.org to share a photo of their foster or adopted dog and answer the question, Why is your dog a lucky dog?
  • To date, Greater Good Charities has provided $18 million in support for COVID-19 disaster-relief, including cash grants, in-kind supplies, and programmatic support.

Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen

Retrieved on: 
Wednesday, March 17, 2021
Design, Innovation, Product management, Clinical, Articles

The collective commercial and scientific expertise of these industry leaders will strengthen Adaptives ability to execute against its open-ended growth story.

Key Points: 
  • The collective commercial and scientific expertise of these industry leaders will strengthen Adaptives ability to execute against its open-ended growth story.
  • I am excited to welcome Leslie and Katey to our Board during this pivotal period of commercial expansion and scientific innovation.
  • Diversity of thought, perspectives, and experience is essential as we seek to transform clinical care in many diagnostic and therapeutic areas, said Chad Robins, chief executive officer of Adaptive Biotechnologies.
  • Leslies expertise will be instrumental in the commercial adoption of Adaptives products into the clinical setting.

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell, IPSCS, Fujifilm, Stem-cell line

As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.

Key Points: 
  • As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.
  • Under the agreement, FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grade iPSC lines) to Sana.
  • FUJIFILM Cellular Dynamics is a leading global player in the field of iPSCs.
  • FUJIFILM Cellular Dynamics, Inc. is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery, contract development and manufacturing services, and cell therapies.

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy

Retrieved on: 
Tuesday, March 16, 2021
Kidney diseases, Medical specialties, Clinical medicine, Medicine, Endothelin receptor antagonist, Atrasentan, IgA nephropathy, Kidney disease, Immunoglobulin A

We look forward to exploring the proteinuria-lowering, anti-inflammatory and anti-fibrotic effects of atrasentan in patients with IgA nephropathy, a serious progressive disease for which there are no approved therapies.

Key Points: 
  • We look forward to exploring the proteinuria-lowering, anti-inflammatory and anti-fibrotic effects of atrasentan in patients with IgA nephropathy, a serious progressive disease for which there are no approved therapies.
  • I am pleased to see Chinook kick off the well-designed phase 3 ALIGN Study of atrasentan in IgA nephropathy.
  • Chinooks lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.
  • BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy.

JetClosing Appoints Anna Collins as President & CEO and Raises $11 Million Series B to Turbo Charge eClosing Solution for Real Estate Agents

Retrieved on: 
Friday, March 12, 2021
Computer companies, Companies, Computing, aQuantive, Escrow, Venture capital, Amazon, Seattle, Microsoft

SEATTLE, March 12, 2021 /PRNewswire/ -- JetClosing ,the leader in 21st century title & escrow, announced hiring Anna Collins as President & CEO and the close of $11 million in Series B funding.

Key Points: 
  • SEATTLE, March 12, 2021 /PRNewswire/ -- JetClosing ,the leader in 21st century title & escrow, announced hiring Anna Collins as President & CEO and the close of $11 million in Series B funding.
  • Collins brings an impressive track record of scaling new businesses and extensive leadership experience to the JetClosing team, having worked at notable technology companies, including Amazon, Microsoft, aQuantive, and several start-ups.
  • Since founding in 2016,JetClosinghas several notable achievements:
    JetClosingis the leading digital title and escrow company for real estate transactions.
  • PSL Ventures is a Seattle-based venture capital fund that invests in early-stage technology companies, primarily based in the Pacific Northwest.

Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

Retrieved on: 
Thursday, March 11, 2021
Gynaecology, Anatomy, Oncology, Medical specialties, Branches of biology, Gynaecological cancer, Ovarian cancer, Cancer, Ovary

The patient has recurrent ovarian cancer and recently underwent functional molecular genomic testing, using 3D tumor organoid cultures grown in the laboratory from the patients tumor.

Key Points: 
  • The patient has recurrent ovarian cancer and recently underwent functional molecular genomic testing, using 3D tumor organoid cultures grown in the laboratory from the patients tumor.
  • If the drug combination shows promise in this patient, Atossa will consider doing additional clinical studies in patients with ovarian cancer.
  • Under the FDA expanded access program, the use of Atossa's proprietary oral Endoxifen is restricted solely to this patient.
  • Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.